Immunosyn and Argyll execs face fraud and insider trading charges

08/2/2011 | Boston Globe (tiered subscription model), The · Reuters

The Securities and Exchange Commission charged four executives of Immunosyn and the company's largest shareholder, Argyll Biotechnologies, with civil fraud, accusing them of lying to investors about the regulatory status of SF-1019, a drug derived from goat's blood that has the potential to treat HIV, multiple sclerosis and other conditions. Three of the executives were also charged with insider trading. An attorney representing the executives didn't return a request for comment.

View Full Article in:

Boston Globe (tiered subscription model), The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ